Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Businesswire·2025-10-20 19:01MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- anro #cns--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The 50 million private placement announced today supports expanded development of ALTO-207, ...